Single-Dose Breakthrough: Acoziborole Signals End of Sleeping Sickness

The recent clinical validation and impending rollout of Acoziborole represent a watershed moment in tropical medicine. For decades, Human African Trypanosomiasis (HAT), commonly known as sleeping sickness, has been a scourge across sub-Saharan Africa, particularly in the Democratic Republic of Congo. The disease, transmitted by the tsetse fly, is notoriously difficult to treat because it progresses from a blood-borne infection (Stage 1) to a central nervous system invasion (Stage 2) that causes neuropsychiatric symptoms, coma, and eventual death. Historically, the treatment was almost as dangerous as the disease itself, often involving toxic arsenic-based injections that required lengthy hospital stays.

Acoziborole changes the fundamental math of disease elimination by offering a single-dose, oral cure that is effective against both stages of the disease. While the introduction of Nifurtimox-Eflornithine Combination Therapy (NECT) in 2009 and the first all-oral treatment, Fexinidazole, in 2018 significantly improved outcomes, they still required complex logistics—multiple days of dosing and, in the case of NECT, intravenous infusions. In the remote, often conflict-ridden regions where HAT persists, the requirement for a 10-day treatment regimen like Fexinidazole creates a massive hurdle for patient compliance and medical follow-up. Acoziborole enables a "screen-and-treat" strategy: a health worker can perform a rapid diagnostic test in a village and, if positive, administer the single dose immediately.

“

The Drugs for Neglected Diseases initiative (DNDi) spearheaded the research, while pharmaceutical giant Sanofi managed the industrial development and clinical trials.

From a market and partnership perspective, the development of Acoziborole is a testament to the success of the Product Development Partnership (PDP) model. The Drugs for Neglected Diseases initiative (DNDi) spearheaded the research, while pharmaceutical giant Sanofi managed the industrial development and clinical trials. Sanofi’s commitment to providing the drug to the World Health Organization (WHO) at no cost ensures that the breakthrough reaches the most vulnerable populations without the traditional barriers of high drug pricing. This model serves as a blueprint for tackling other neglected tropical diseases (NTDs) that do not offer traditional commercial incentives for the private sector.